In an effort to minimize the risk of medication errors due to proprietary name confusion, the FDA performs comprehensive safety reviews of proposed proprietary names for all drug and biologic applications it receives each year. Safety reviews include the use of the Phonetic and Orthographic Computer Analysis (POCA) software that uses an algorithm to calculate orthographic and phonetic similarity scores for name pairs. Higher scores indicate name pairs that are more similar and more likely to be confused. This is just one part of the review process the FDA uses in determining the risk of name confusion for a name pair. Providing this software algorithm to the public allows sponsors to screen proposed proprietary names for high similarity scores prior to submitting proposed proprietary names to the Agency for review. This software application uses Drugs@FDA and RxNorm as the two data sources with marketed names that are updated monthly. Additional search capabilities provided in POCA include the United States Adopted Names (USAN) Council stem search algorithm and the non-proprietary name biologic suffix search tool. The latter allows users to search candidate suffixes against suffixes that are already approved and marketed for orthographic and phonetic similarity. This system will not store searches performed by users and provides the necessary security to maintain proprietary information confidentially for each user. Users may access this system anonymously and no user personal information is intercepted or monitored by this system.
Use of this system and/or attainment of a certain POCA score does not guarantee any result with respect to FDA’s determination regarding the safety of a proposed proprietary name. Use of this system is for the user’s evaluation only. Such use does not establish or reserve any rights to proposed proprietary names.